SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette syndrome ("TS").
The work towards an IND submission is intended to open a U.S. clinical site that will take part in the phase IIb trial.
